Overview
- Sun Pharmaceutical announced that the U.S. FDA approved a supplemental BLA for ILUMYA (tildrakizumab‑asmn) for adults with active psoriatic arthritis on Oct. 30, 2026.
- The approval was supported by two global Phase 3 INSPIRE studies (INSPIRE‑1 and INSPIRE‑2) that showed tildrakizumab was superior to placebo on the primary ACR20 endpoint at 24 weeks after two initial doses.
- Safety findings in INSPIRE matched ILUMYA’s established profile with no new safety signals reported, and the label warns of increased infection risk and requires tuberculosis screening before starting treatment.
- The drug is given by a healthcare provider, a positioning Sun Pharma says will help patients who cannot self‑inject and strengthen the company’s psoriatic disease portfolio; markets reacted with a rise in Sun Pharma shares.
- Sun Pharma said integration planning for its planned Organon acquisition is progressing and regulatory approvals have been secured in most regions, while the company highlights that about 2.4 million Americans live with psoriatic arthritis.